Screener
Medpace Holdings, Inc. MEDP Central Nervous System — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Therapeutic Area | ||||
| Metabolic | $219,067 | $147,873 | $456,625 | $295,888 |
| Oncology | 209,372 | 188,558 | 410,611 | 359,034 |
| Other | 98,279 | 118,062 | 191,597 | 213,898 |
| Central Nervous System | 82,858 | 61,129 | 163,065 | 116,030 |
| Cardiology | 59,982 | 58,584 | 116,243 | 116,863 |
| AVAI | 37,773 | 29,105 | 75,794 | 60,168 |
| Total revenue | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s central nervous system — total revenue?
- Medpace Holdings, Inc. (MEDP) reported central nervous system — total revenue of $59.98M in Q2 2026.
- How has Medpace Holdings, Inc.'s central nervous system — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s central nervous system — total revenue increased by 2.4% year-over-year, from $58.58M to $59.98M.
- What is the long-term trend for Medpace Holdings, Inc.'s central nervous system — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s central nervous system — total revenue has grown at a 18.9% compound annual growth rate (CAGR), from $119.69M to $239.37M.
- What does central nervous system — total revenue mean?
- This metric represents the total gross revenue generated from clinical research and development services specifically focused on Central Nervous System (CNS) therapeutic trials. It captures the financial performance of the company's specialized expertise in managing complex neurological and psychiatric drug development programs for biotechnology and pharmaceutical clients. This revenue stream reflects the demand for specialized clinical trial management, regulatory support, and site monitoring within the CNS therapeutic area.
Ask your AI about Medpace Holdings, Inc.'s central nervous system — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude